Preclinical Drug Development

## Purpose of Preclinical Development

Preclinical development bridges drug discovery and clinical trials. Its primary goal is to generate the safety, pharmacology, and manufacturing data required to support an Investigational New Drug (IND) application and justify the first dose in humans. This phase typically takes 1-2 years and costs $5-20 million.

## GLP Toxicology Studies

Good Laboratory Practice (GLP) toxicology studies are the cornerstone of preclinical safety assessment. Regulatory guidelines (ICH M3) specify requirements:

**General toxicity studies**: Repeated-dose studies in two species (one rodent, one non-rodent, typically rat and dog or non-human primate). Duration depends on planned clinical trial length. For Phase I single-dose studies, 2-week rodent and non-rodent GLP studies may suffice. Endpoints include clinical observations, body weight, food consumption, clinical pathology (hematology, chemistry), organ weights, and histopathology of 40+ tissues.

**Genetic toxicology**: Standard battery includes in vitro bacterial reverse mutation (Ames), in vitro chromosomal aberration or micronucleus, and in vivo micronucleus assay. Any positive result requires mechanistic follow-up.

**Safety pharmacology (ICH S7A/B)**: Core battery assesses cardiovascular (hERG, telemetry in conscious dog), central nervous system (Irwin/FOB in rat), and respiratory (plethysmography in rat) systems.

## ADME and Pharmacokinetic Studies

Definitive preclinical PK studies characterize the drug's behavior in vivo:

- **Single-dose PK**: IV and oral dosing in rat, dog, and/or NHP to determine clearance, volume of distribution, bioavailability, and half-life
- **Mass balance/ADME**: Radiolabeled drug study to determine routes and extent of excretion (urine, feces, bile)
- **Metabolite identification**: In vitro and in vivo metabolite profiling across species. Human-unique metabolites above 10% of total drug-related exposure require separate safety assessment (MIST guidance)
- **Drug-drug interaction potential**: CYP inhibition/induction, transporter substrate/inhibitor profiling

## Formulation Development

Preclinical formulations are developed to support both toxicology studies and initial clinical supplies:

- **Oral formulations**: Solutions, suspensions, or capsules for toxicology. Clinical formulation development (tablets, capsules) begins in parallel
- **IV formulations**: Required for PK bridging and sometimes Phase I
- **Stability studies**: ICH-guided stability under various conditions to establish shelf life and storage requirements

## Manufacturing and CMC

Chemistry, Manufacturing, and Controls (CMC) documentation supports the IND application. Requirements include defined synthetic route with quality controls at each step, analytical methods for identity, purity, and potency, specifications for drug substance and drug product, and GMP manufacturing of clinical trial material.

Process development scales synthesis from grams (discovery) to kilograms (clinical supply). Impurity profiling ensures that synthetic impurities are controlled below ICH Q3A thresholds.

## First-in-Human Dose Selection

The starting dose for Phase I is derived from preclinical data using the NOAEL (no observed adverse effect level) approach. The NOAEL from the most sensitive species is converted to a human equivalent dose (HED) using body surface area scaling, then divided by a safety factor (typically 10x). For biologics and high-risk molecules, the MABEL (minimum anticipated biological effect level) approach may be used instead.

## Key Takeaways

- GLP toxicology in two species is mandatory before first-in-human dosing
- ADME studies must identify human-unique metabolites requiring separate safety testing
- First-in-human dose selection uses NOAEL-to-HED conversion with 10x safety margin
- CMC development ensures reproducible GMP manufacturing of clinical trial material